Domača stranGNLX • NASDAQ
add
Genelux Corp
Prejšnji trg. dan.
2,49 $
Dnevni razpon
2,48 $ - 2,70 $
Letni razpon
1,60 $ - 16,60 $
Tržna kapitalizacija
91,25 mio. USD
Povprečni obseg
192,00 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | — | — |
Stroški poslovanja | 6,94 mio. | 30,79 % |
Čisti dohodek | −6,47 mio. | −20,99 % |
Čista dobičkovnost prihodkov | — | — |
Earnings per share | −0,19 | 5,00 % |
EBITDA | −6,88 mio. | −33,07 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 34,06 mio. | 14,02 % |
Skupna sredstva | 40,27 mio. | 18,19 % |
Skupne obveznosti | 7,18 mio. | −28,52 % |
Celoten lastniški kapital | 33,09 mio. | — |
Shares outstanding | 34,54 mio. | — |
Razmerje P/B | 2,59 | — |
Donosnost sredstev | −40,61 % | — |
Donosnost kapitala | −46,27 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −6,47 mio. | −20,99 % |
Denar iz dejavnosti | −5,75 mio. | −71,22 % |
Denar iz naložb | 3,99 mio. | 1.541,16 % |
Denar iz financiranja | 0,00 | −100,00 % |
Neto sprememba denarnih sredstev | −1,76 mio. | −164,35 % |
Prost denarni tok | −4,98 mio. | −236,07 % |
Vizitka
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Datum ustanovitve
2001
Sedež organizacije
Spletno mesto
Zaposleni
24
